Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814938 · ClinicalTrials.gov registry record · Phase 4
A Study of a Novel Precision Medicine Approach For Obesity
A Phase 4 study of Obesity, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 135
- Enrollment target
- 2
- Study locations
NCT06814938 is a Phase 4 study of Obesity that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 135 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06814938, a Phase 4 study of Obesity, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 135 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2028-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06814938
The ClinicalTrials.gov registry entry for NCT06814938 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (84% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06814938 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06814938 about?
NCT06814938 is a clinical study titled "A Study of a Novel Precision Medicine Approach For Obesity". This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
What is the current status of trial NCT06814938?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 135 participants. The study started on 2025-02-21. Estimated completion is 2028-11.
What conditions does trial NCT06814938 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06814938?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06814938?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06814938 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.